董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Louis J. Grabowsky | 男 | Director | 75 | 0.16万美元 | 未持股 | 2019-02-13 |
| Claes Glassell | 男 | Director | 75 | 未披露 | 未持股 | 2019-02-13 |
| Bernhard Hampl | 男 | Director | 76 | 0.03万美元 | 未持股 | 2019-02-13 |
| Gregory B. Brown | -- | Director | -- | 未披露 | 未持股 | 2019-02-13 |
| Claes Glassell | 男 | Director | 75 | 0.16万美元 | 未持股 | 2019-02-13 |
| Shlomo Yanai | 男 | Chairman of the Board of Director | 74 | 0.16万美元 | 未持股 | 2019-02-13 |
| Ilan Kaufthal | 男 | Director | 78 | 0.16万美元 | 未持股 | 2019-02-13 |
| Steven M. Klosk | 男 | President, Chief Executive Officer and Director | 61 | 378.25万美元 | 未持股 | 2019-02-13 |
| Kathryn Rudie Harrigan | 女 | Director | 75 | 0.16万美元 | 未持股 | 2019-02-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samantha M. Hanley | 女 | Vice President, General Counsel, and Secretary | 41 | 95.89万美元 | 未持股 | 2019-02-13 |
| Steven M. Klosk | 男 | President, Chief Executive Officer and Director | 61 | 378.25万美元 | 未持股 | 2019-02-13 |
| Gregory P. Sargen | 男 | Chief Financial Officer and Executive Vice President, Corporate Development and Strategy | 53 | 249.85万美元 | 未持股 | 2019-02-13 |
| Shawn P. Cavanagh | 男 | Executive Vice President and Chief Operating Officer | 52 | 277.99万美元 | 未持股 | 2019-02-13 |
| James G. Farrell | 男 | Vice President and Corporate Controller | 52 | 未披露 | 未持股 | 2019-02-13 |
董事简历
中英对照 | 中文 | 英文- Louis J. Grabowsky
-
Louis J. Grabowsky自2015年起担任Griffon Corporation董事。他是Juniper Capital Management的创始人兼负责人，Juniper Capital Management是一家为高增长潜力但资源不足的美国创业公司提供资金的金融赞助商。在创立Juniper Capital之前，Grabowsky先生于2002年至2014年担任Grant Thornton LLP的合伙人，于2009年至2013年担任首席运营官，并于2013年至2014年7月退休担任运营高级顾问。Grabowsky先生目前在Juniper Capital作为投资者的各种投资组合公司的董事会任职。
Louis J. Grabowsky Mr. Louis J. Grabowsky has been a Director since 2015. He is a founder and principal of Juniper Capital Management, a financial sponsor that provides capital to high growth potential but under resced U.S. entrepreneurial companies. Prior to founding Juniper Capital, Mr. Grabowsky was a partner at Grant Thornton LLP from 2002 to 2014, serving as Chief Operating Officer from 2009 to 2013 and Senior Advisor, Operations from 2013 until his retirement in July 2014. Mr. Grabowsky currently serves on the boards of vario portfolio companies in which Juniper Capital is an investor. From 2015 to 2019, Mr. Grabowsky served on the Board of Directors of Cambrex Corporation (NYSE: CBM). Mr. Grabowsky brings to the Board and the Audit Committee an in depth understanding of the financial reporting, auditing and accounting issues that come before the Board and the Audit Committee. - Louis J. Grabowsky自2015年起担任Griffon Corporation董事。他是Juniper Capital Management的创始人兼负责人，Juniper Capital Management是一家为高增长潜力但资源不足的美国创业公司提供资金的金融赞助商。在创立Juniper Capital之前，Grabowsky先生于2002年至2014年担任Grant Thornton LLP的合伙人，于2009年至2013年担任首席运营官，并于2013年至2014年7月退休担任运营高级顾问。Grabowsky先生目前在Juniper Capital作为投资者的各种投资组合公司的董事会任职。
- Louis J. Grabowsky Mr. Louis J. Grabowsky has been a Director since 2015. He is a founder and principal of Juniper Capital Management, a financial sponsor that provides capital to high growth potential but under resced U.S. entrepreneurial companies. Prior to founding Juniper Capital, Mr. Grabowsky was a partner at Grant Thornton LLP from 2002 to 2014, serving as Chief Operating Officer from 2009 to 2013 and Senior Advisor, Operations from 2013 until his retirement in July 2014. Mr. Grabowsky currently serves on the boards of vario portfolio companies in which Juniper Capital is an investor. From 2015 to 2019, Mr. Grabowsky served on the Board of Directors of Cambrex Corporation (NYSE: CBM). Mr. Grabowsky brings to the Board and the Audit Committee an in depth understanding of the financial reporting, auditing and accounting issues that come before the Board and the Audit Committee.
- Claes Glassell
-
Claes Glassell 2011年至2015年是CMC Biologics（一家合同生产组织，专注于生物制药）的首席执行官。2011年至2004年，Glassell先生是Cerus Corp.（一家公开上市医疗器械公司）的首席执行官。在加入Cerus Corp.之前，Glassell先生在Cambrex Corporation担任8年多的总裁兼首席运营官。1989年至1994年，Glassell先生是Nobel Chemicals的总裁兼首席执行官和Nobel Industries的高级副总裁。
Claes Glassell, Director since 2016. Member of the Audit and Regulatory Affairs Committees of the Board. Mr. Glassell was Chief Executive Officer of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals from 2011 through 2015. From 2004 through 2011 Mr. Glassell was Chief Executive officer of Cerus Corp., a publically held medical device company. Before joining Cerus Corp., Mr. Glassell spent over eight years at Cambrex Corporation as President and Chief Operating Officer. From 1989 through 1994 Mr. Glassell was President and CEO of Nobel Chemicals and Senior Vice President of Nobel Industries. - Claes Glassell 2011年至2015年是CMC Biologics（一家合同生产组织，专注于生物制药）的首席执行官。2011年至2004年，Glassell先生是Cerus Corp.（一家公开上市医疗器械公司）的首席执行官。在加入Cerus Corp.之前，Glassell先生在Cambrex Corporation担任8年多的总裁兼首席运营官。1989年至1994年，Glassell先生是Nobel Chemicals的总裁兼首席执行官和Nobel Industries的高级副总裁。
- Claes Glassell, Director since 2016. Member of the Audit and Regulatory Affairs Committees of the Board. Mr. Glassell was Chief Executive Officer of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals from 2011 through 2015. From 2004 through 2011 Mr. Glassell was Chief Executive officer of Cerus Corp., a publically held medical device company. Before joining Cerus Corp., Mr. Glassell spent over eight years at Cambrex Corporation as President and Chief Operating Officer. From 1989 through 1994 Mr. Glassell was President and CEO of Nobel Chemicals and Senior Vice President of Nobel Industries.
- Bernhard Hampl
-
Bernhard Hampl，自2016年起担任董事。监管事务委员会成员，Hampl博士是BKH Pharma Services的总裁，这是一家制药咨询公司。Hampl从1996年到2005年担任纽约Eon Labs，Inc.（一家专门从事仿制药开发、制造和营销的公司）总裁和首席执行官。Hampl博士目前担任Softbox Systems Ltd的董事会联合主席，该公司是一家总部位于英国的专门从事冷链运输的公司。他也是SiO2Medical公司的董事会成员，以及Formycon AG公司（生物技术公司，位于德国慕尼黑）的科学顾问委员会的成员，以及Great Point Partners公司（投资公司，位于康涅狄格州格林威治）的首席执行官兼顾问委员会的成员。Hampl博士也是Advent International（一家全球私募股权公司）的独立顾问和顾问。Hampl博士曾就读于德国慕尼黑the Ludwig Maximilian University的药学院，是一名注册药剂师，持有同一所大学的药物化学博士学位。
Bernhard Hampl, Director since 2016. Member of the Regulatory Affairs Committee, Dr. Hampl is the President of BKH Pharma Services, a pharmaceutical consultancy firm. From 1996 to 2005 Dr. Hampl was President and CEO of Eon Labs, Inc. in NY, a company specializing in the development, manufacturing and marketing of generic pharmaceuticals. Dr. Hampl currently serves as Co-Chairman of the Board of Softbox Sytems LTD, a UK based company specializing in cold chain shipping. He is also a member of the Board of SiO2 Medical, as well as a member of the scientific advisory Board of Formycon AG, a biotech company in Munich, Germany, and the CEO- Advisory Board of Great Point Partners, an investment firm in Greenwich, CT. Dr. Hampl is also an independent consultant and advisor to Advent International, a global private equity firm. Dr. Hampl attended the School of Pharmacy of the Ludwig Maximilian University of Munich, Germany, and is a registered pharmacist who holds a PhD in Pharmaceutical Chemistry from the same university. - Bernhard Hampl，自2016年起担任董事。监管事务委员会成员，Hampl博士是BKH Pharma Services的总裁，这是一家制药咨询公司。Hampl从1996年到2005年担任纽约Eon Labs，Inc.（一家专门从事仿制药开发、制造和营销的公司）总裁和首席执行官。Hampl博士目前担任Softbox Systems Ltd的董事会联合主席，该公司是一家总部位于英国的专门从事冷链运输的公司。他也是SiO2Medical公司的董事会成员，以及Formycon AG公司（生物技术公司，位于德国慕尼黑）的科学顾问委员会的成员，以及Great Point Partners公司（投资公司，位于康涅狄格州格林威治）的首席执行官兼顾问委员会的成员。Hampl博士也是Advent International（一家全球私募股权公司）的独立顾问和顾问。Hampl博士曾就读于德国慕尼黑the Ludwig Maximilian University的药学院，是一名注册药剂师，持有同一所大学的药物化学博士学位。
- Bernhard Hampl, Director since 2016. Member of the Regulatory Affairs Committee, Dr. Hampl is the President of BKH Pharma Services, a pharmaceutical consultancy firm. From 1996 to 2005 Dr. Hampl was President and CEO of Eon Labs, Inc. in NY, a company specializing in the development, manufacturing and marketing of generic pharmaceuticals. Dr. Hampl currently serves as Co-Chairman of the Board of Softbox Sytems LTD, a UK based company specializing in cold chain shipping. He is also a member of the Board of SiO2 Medical, as well as a member of the scientific advisory Board of Formycon AG, a biotech company in Munich, Germany, and the CEO- Advisory Board of Great Point Partners, an investment firm in Greenwich, CT. Dr. Hampl is also an independent consultant and advisor to Advent International, a global private equity firm. Dr. Hampl attended the School of Pharmacy of the Ludwig Maximilian University of Munich, Germany, and is a registered pharmacist who holds a PhD in Pharmaceutical Chemistry from the same university.
- Gregory B. Brown
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Claes Glassell
-
Claes Glassell，2016年起担任Cambrex公司董事。董事会审计和监管事务委员会成员。格拉塞尔先生是CMC Biologics的首席执行官，CMC Biologics是一家合同制企业，从2011年到2015年专注于生物制药。从2004年到2011年，格拉塞尔一直担任Cerus公司（Cerus Corp.）的首席执行官，Cerus是一家公共医疗设备公司公司。克莱斯Glassell自2004年5月起担任我们的总裁兼首席执行官和董事会成员。格拉塞尔先生是总裁，2001年7月至2003年1月期间担任Cambrex Corporation首席运营官和董事，1994年至2001年期间在Cambrex Corporation担任管理职务，2000年至2001年期间担任执行副总裁和首席运营官，1994年至2000年期间担任Cambrex Limited副总裁和常务董事。在此之前，Glassell先生曾担任阿克苏诺贝尔制药化学业务区总裁兼首席执行官，并在美国、英国和瑞典的Berol担任过多项国际管理职务。Glassell先生于1993年至1996年在瑞典化学工业协会董事会任职，同时也是瑞典化学工业协会责任关怀委员会的成员。Glassell先生是CMC Biopharmaceuticals A/S的董事会成员，CMC Biopharmaceuticals A/S是一家合同制造机构。
Claes Glassell, Director since 2016,Cambrex Corporation. Member of the Audit and Regulatory Affairs Committees of the Board. Mr. Glassell was Chief Executive Officer of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals from 2011 through 2015. From 2004 through 2011 Mr. Glassell was Chief Executive officer of Cerus Corp., a publically held medical device company.Claes Glassell,has served as Cambrex Corporation's President and Chief Executive Officer and a member of Cambrex Corporation's Board since May 2004. Mr. Glassell was President, Chief Operating Officer and a director of Cambrex Corporation from July 2001 until January 2003 and held management positions at Cambrex Corporation from 1994 until 2001 including Executive Vice President and Chief Operating Officer from 2000 until 2001 and Vice President and Managing Director of Cambrex Limited from 1994 until 2000. Previously, Mr. Glassell was President and Chief Executive Officer of the Pharma Chemistry Business Area of Akzo Nobel and held various international management assignments with Berol in the United States, United Kingdom and Sweden. Mr. Glassell served on the Board of the Swedish Chemical Industry Association from 1993 until 1996 and also was a member of the Responsible Care Committee for the Swedish Chemical Industry Association. Mr. Glassell serves on the board of directors of CMC Biopharmaceuticals A/S, a contract manufacturing organization. - Claes Glassell，2016年起担任Cambrex公司董事。董事会审计和监管事务委员会成员。格拉塞尔先生是CMC Biologics的首席执行官，CMC Biologics是一家合同制企业，从2011年到2015年专注于生物制药。从2004年到2011年，格拉塞尔一直担任Cerus公司（Cerus Corp.）的首席执行官，Cerus是一家公共医疗设备公司公司。克莱斯Glassell自2004年5月起担任我们的总裁兼首席执行官和董事会成员。格拉塞尔先生是总裁，2001年7月至2003年1月期间担任Cambrex Corporation首席运营官和董事，1994年至2001年期间在Cambrex Corporation担任管理职务，2000年至2001年期间担任执行副总裁和首席运营官，1994年至2000年期间担任Cambrex Limited副总裁和常务董事。在此之前，Glassell先生曾担任阿克苏诺贝尔制药化学业务区总裁兼首席执行官，并在美国、英国和瑞典的Berol担任过多项国际管理职务。Glassell先生于1993年至1996年在瑞典化学工业协会董事会任职，同时也是瑞典化学工业协会责任关怀委员会的成员。Glassell先生是CMC Biopharmaceuticals A/S的董事会成员，CMC Biopharmaceuticals A/S是一家合同制造机构。
- Claes Glassell, Director since 2016,Cambrex Corporation. Member of the Audit and Regulatory Affairs Committees of the Board. Mr. Glassell was Chief Executive Officer of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals from 2011 through 2015. From 2004 through 2011 Mr. Glassell was Chief Executive officer of Cerus Corp., a publically held medical device company.Claes Glassell,has served as Cambrex Corporation's President and Chief Executive Officer and a member of Cambrex Corporation's Board since May 2004. Mr. Glassell was President, Chief Operating Officer and a director of Cambrex Corporation from July 2001 until January 2003 and held management positions at Cambrex Corporation from 1994 until 2001 including Executive Vice President and Chief Operating Officer from 2000 until 2001 and Vice President and Managing Director of Cambrex Limited from 1994 until 2000. Previously, Mr. Glassell was President and Chief Executive Officer of the Pharma Chemistry Business Area of Akzo Nobel and held various international management assignments with Berol in the United States, United Kingdom and Sweden. Mr. Glassell served on the Board of the Swedish Chemical Industry Association from 1993 until 1996 and also was a member of the Responsible Care Committee for the Swedish Chemical Industry Association. Mr. Glassell serves on the board of directors of CMC Biopharmaceuticals A/S, a contract manufacturing organization.
- Shlomo Yanai
-
Shlomo Yanai，自2019年12月起担任董事会成员。Yanai先生拥有超过17年的企业领导经验，主要在制药行业。2007年至2012年，Yanai先生担任Teva Pharmaceutical Industries Ltd.的总裁兼首席执行官。在此之前，他从2002年到2006年担任Adama Industries的首席执行官。Yanai先生目前担任Lumenis Ltd.的董事会主席、Philip Morris的董事会成员、Moelis & Company的高级顾问。此前，他曾担任Rothschild Caesarea Foundation的副主席、Cambrex Corporation的董事会主席、Protalix Biotherapeutics、PDL BioPharma Inc.、Perrigo Company、Sagent Pharmaceuticals、Elisra、Bank Leumi Lelsreal和I.T.L. Optronics Ltd.的董事，以及W. R. Grace的董事会成员（2018-2021）。Yanai先生还在以色列国防军担任过各种领导职务。Yanai先生毕业于哈佛商学院（Harvard Business School）的AMP项目。他持有乔治华盛顿大学公共管理硕士学位和Tel Aviv大学学士学位，也是美国国防大学战争学院的毕业生。
Shlomo Yanai,has served on Board of Directors since December 2019. Mr. Yanai has more than 17 years of corporate leadership experience, primarily in the pharmaceutical industry. Mr. Yanai served as President and Chief Executive Officer at Teva Pharmaceutical Industries Ltd. from 2007 to 2012. Prior to that, Mr. Yanai was the CEO of Adama Industries from 2002 to 2006. Mr. Yanai currently serves as the Chairman of the Board of Lumenis Ltd., a Board member at Philip Morris, and a senior advisor to Moelis & Company. Mr. Yanai previously served as Vice Chairman of the Rothschild Caesarea Foundation, Chairman of the Board of Cambrex Corporation and director of Protalix Biotherapeutics, PDL BioPharma Inc., Perrigo Company, Sagent Pharmaceuticals, Elisra, Bank Leumi Lelsreal, and I.T.L. Optronics Ltd. and a Board member of W. R. Grace from 2018-2021. Mr. Yanai also held various leadership positions in the Israel Defense Forces. Mr. Yanai is a graduate of Harvard Business School's AMP program. He holds a Master of Public Administration degree from George Washington University and a B.A. degree from Tel Aviv University and is also a graduate of the U.S. National Defense University – War College. - Shlomo Yanai，自2019年12月起担任董事会成员。Yanai先生拥有超过17年的企业领导经验，主要在制药行业。2007年至2012年，Yanai先生担任Teva Pharmaceutical Industries Ltd.的总裁兼首席执行官。在此之前，他从2002年到2006年担任Adama Industries的首席执行官。Yanai先生目前担任Lumenis Ltd.的董事会主席、Philip Morris的董事会成员、Moelis & Company的高级顾问。此前，他曾担任Rothschild Caesarea Foundation的副主席、Cambrex Corporation的董事会主席、Protalix Biotherapeutics、PDL BioPharma Inc.、Perrigo Company、Sagent Pharmaceuticals、Elisra、Bank Leumi Lelsreal和I.T.L. Optronics Ltd.的董事，以及W. R. Grace的董事会成员（2018-2021）。Yanai先生还在以色列国防军担任过各种领导职务。Yanai先生毕业于哈佛商学院（Harvard Business School）的AMP项目。他持有乔治华盛顿大学公共管理硕士学位和Tel Aviv大学学士学位，也是美国国防大学战争学院的毕业生。
- Shlomo Yanai,has served on Board of Directors since December 2019. Mr. Yanai has more than 17 years of corporate leadership experience, primarily in the pharmaceutical industry. Mr. Yanai served as President and Chief Executive Officer at Teva Pharmaceutical Industries Ltd. from 2007 to 2012. Prior to that, Mr. Yanai was the CEO of Adama Industries from 2002 to 2006. Mr. Yanai currently serves as the Chairman of the Board of Lumenis Ltd., a Board member at Philip Morris, and a senior advisor to Moelis & Company. Mr. Yanai previously served as Vice Chairman of the Rothschild Caesarea Foundation, Chairman of the Board of Cambrex Corporation and director of Protalix Biotherapeutics, PDL BioPharma Inc., Perrigo Company, Sagent Pharmaceuticals, Elisra, Bank Leumi Lelsreal, and I.T.L. Optronics Ltd. and a Board member of W. R. Grace from 2018-2021. Mr. Yanai also held various leadership positions in the Israel Defense Forces. Mr. Yanai is a graduate of Harvard Business School's AMP program. He holds a Master of Public Administration degree from George Washington University and a B.A. degree from Tel Aviv University and is also a graduate of the U.S. National Defense University – War College.
- Ilan Kaufthal
-
Ilan Kaufthal于1983年公司成立起担任董事。审计委员及董事会薪酬委员会成员。 现为East Wind Advisors（经纪自营商）的董事长。目前担任Tronox公司（总部设在康涅狄格州斯坦福的二氧化钛颜料公开上市的生产商），Blyth, Inc.（总部设在康涅狄格州格林威治的一家公开上市的多层次营销公司），Quin Pario Acquisition Corporation（用于实现合并、资本股票交易、资产收购、股权收购、重组或类似业务合并的公司），Edmunds.com（一个私人公司）POOF -Slinky Inc.，（一个品牌的儿童消费产品业务公司）的董事局成员。从2000年5月至2008年6月担任Bear, Stearns & Co. Inc.的投资银行副主席。加盟该公司前，他是Schroder & Co. Incorporated的副董事长和并购主管，工作13年。在此之前，他在NL工业公司（化工和石油服务行业的公司）工作，担任其高级副总裁兼首席财务官。
Ilan Kaufthal has served as a director since November 2014. Mr. Kaufthal is Chairman of East Wind Advisors, a specialized investment banking firm serving companies in the media, education, consumer/retail and information industries, and has held such position since May 2011. From July 2008 to July 2013 Mr. Kaufthal served as Senior Advisor at Irving Place Capital. Earlier in his career, he was Vice Chairman of Investment Banking at Bear Stearns & Co. from May 2000 to July 2008 Vice Chairman and Head of Mergers and Acquisitions at Schroder & Co. from February 1987 to May 2000 and SVP and CFO at NL Industries from May 1971 to February 1987. Mr. Kaufthal serves on the board of directors of the following public companies: Cambrex Corporation NYSE:CBM, a supplier to the pharmaceutical industries, and Tronox Limited (NYSE:TROX), a fully integrated producer and marketer of titanium ore and titanium dioxide pigment. He previously served as a director of Quinpario 1. Mr. Kaufthal is a graduate of Columbia University and the New York University Graduate School of Business Administration. - Ilan Kaufthal于1983年公司成立起担任董事。审计委员及董事会薪酬委员会成员。 现为East Wind Advisors（经纪自营商）的董事长。目前担任Tronox公司（总部设在康涅狄格州斯坦福的二氧化钛颜料公开上市的生产商），Blyth, Inc.（总部设在康涅狄格州格林威治的一家公开上市的多层次营销公司），Quin Pario Acquisition Corporation（用于实现合并、资本股票交易、资产收购、股权收购、重组或类似业务合并的公司），Edmunds.com（一个私人公司）POOF -Slinky Inc.，（一个品牌的儿童消费产品业务公司）的董事局成员。从2000年5月至2008年6月担任Bear, Stearns & Co. Inc.的投资银行副主席。加盟该公司前，他是Schroder & Co. Incorporated的副董事长和并购主管，工作13年。在此之前，他在NL工业公司（化工和石油服务行业的公司）工作，担任其高级副总裁兼首席财务官。
- Ilan Kaufthal has served as a director since November 2014. Mr. Kaufthal is Chairman of East Wind Advisors, a specialized investment banking firm serving companies in the media, education, consumer/retail and information industries, and has held such position since May 2011. From July 2008 to July 2013 Mr. Kaufthal served as Senior Advisor at Irving Place Capital. Earlier in his career, he was Vice Chairman of Investment Banking at Bear Stearns & Co. from May 2000 to July 2008 Vice Chairman and Head of Mergers and Acquisitions at Schroder & Co. from February 1987 to May 2000 and SVP and CFO at NL Industries from May 1971 to February 1987. Mr. Kaufthal serves on the board of directors of the following public companies: Cambrex Corporation NYSE:CBM, a supplier to the pharmaceutical industries, and Tronox Limited (NYSE:TROX), a fully integrated producer and marketer of titanium ore and titanium dioxide pigment. He previously served as a director of Quinpario 1. Mr. Kaufthal is a graduate of Columbia University and the New York University Graduate School of Business Administration.
- Steven M. Klosk
-
Steven M. Klosk自2008年起担任董事。于1992年加入Cambrex公司，当选Cambrex公司的总裁和行政总裁，于2008年5月成为董事会的一员。在2007年，被任命为Cambrex公司的执行副总裁兼首席营运官，负责制药业务。从2005年至2007年担任制药公司和生物制药事业部的执行副总裁兼首席运营官。1992年至2005年，担任越来越多的要职，包括执行副总裁，负责管理。目前担任NPS（一家私人持有的包装公司）的董事，以及在新泽西州帕特森的圣若瑟医院基金董事会的董事。
Steven M. Klosk joined board of directors in 2014. He is a senior executive with extensive management experience in the life sciences indtry. He served as a Director at Cambrex Corporation (NYSE:CBM) from May 2008 through December 2019, until it was acquired by Permira and then as Director from December 2019 until June 2020. Cambrex is one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets, where he served as President and Chief Executive Officer from May 2008 through June 2020. In that role he was responsible for all aspects of Cambrex's global biness with manufacturing and R&D facilities in the United States, Sden, Italy, Estonia, Canada, Scotland, and Germany.From 2021 until April 2024, he served on the board of directors of Recipharm, a leading pharmaceutical contract development & manufacturing organization. Since 2021 he has served on the board of Formulated Solutions, a topicals contract development & manufacturing organization where he is the chairman of the board and BioIVT, a leading supplier of biologics specimens for biotech research. In addition, Mr. Klosk served on the board of Golden Arrow Merger Corp., which merged in Augt 2024 with Bolt Project Holdings Inc. (Nasdaq: BSLK), a pioneer in stainable biomaterials for consumer products. Mr. Klosk served both as a board member and an audit committee member of Bolt Project Holdings until February 2025. Mr. Klosk previoly served on the boards of BIOVECTRA, a leading small molecule and biologics CDMO until September 2024 and NJ Bio, a leading antibody drug conjugate contract research organization from March 2021 through December 2024.Mr. Klosk held other executive positions at Cambrex Corporation, including President, Executive Vice President & COO as ll as President, Pharma Biness Unit (2007 2008) where he had full P&L and balance sheet responsibility for f operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Biness Unit (2003 2007) where he was responsible for managing a highly profitable global biness with six operating units in North America and Europe. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School. - Steven M. Klosk自2008年起担任董事。于1992年加入Cambrex公司，当选Cambrex公司的总裁和行政总裁，于2008年5月成为董事会的一员。在2007年，被任命为Cambrex公司的执行副总裁兼首席营运官，负责制药业务。从2005年至2007年担任制药公司和生物制药事业部的执行副总裁兼首席运营官。1992年至2005年，担任越来越多的要职，包括执行副总裁，负责管理。目前担任NPS（一家私人持有的包装公司）的董事，以及在新泽西州帕特森的圣若瑟医院基金董事会的董事。
- Steven M. Klosk joined board of directors in 2014. He is a senior executive with extensive management experience in the life sciences indtry. He served as a Director at Cambrex Corporation (NYSE:CBM) from May 2008 through December 2019, until it was acquired by Permira and then as Director from December 2019 until June 2020. Cambrex is one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets, where he served as President and Chief Executive Officer from May 2008 through June 2020. In that role he was responsible for all aspects of Cambrex's global biness with manufacturing and R&D facilities in the United States, Sden, Italy, Estonia, Canada, Scotland, and Germany.From 2021 until April 2024, he served on the board of directors of Recipharm, a leading pharmaceutical contract development & manufacturing organization. Since 2021 he has served on the board of Formulated Solutions, a topicals contract development & manufacturing organization where he is the chairman of the board and BioIVT, a leading supplier of biologics specimens for biotech research. In addition, Mr. Klosk served on the board of Golden Arrow Merger Corp., which merged in Augt 2024 with Bolt Project Holdings Inc. (Nasdaq: BSLK), a pioneer in stainable biomaterials for consumer products. Mr. Klosk served both as a board member and an audit committee member of Bolt Project Holdings until February 2025. Mr. Klosk previoly served on the boards of BIOVECTRA, a leading small molecule and biologics CDMO until September 2024 and NJ Bio, a leading antibody drug conjugate contract research organization from March 2021 through December 2024.Mr. Klosk held other executive positions at Cambrex Corporation, including President, Executive Vice President & COO as ll as President, Pharma Biness Unit (2007 2008) where he had full P&L and balance sheet responsibility for f operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Biness Unit (2003 2007) where he was responsible for managing a highly profitable global biness with six operating units in North America and Europe. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School.
- Kathryn Rudie Harrigan
-
Kathryn Rudie Harrigan自1994年起担任董事。审计和监管事务委员会成员。 1993年，成为哥伦比亚大学商学院的第一个Henry R. Kravis教授。曾任哥伦比亚大学商学院管理科教授，和Jerome A. Chazen学院的学术主任，国际商业和战略研究中心学术主任，均位于哥伦比亚大学。她是战略管理协会的创始成员之一。她曾执教哥伦比亚大学商学院的行政人员培训课程，欧洲伦敦和布鲁塞尔的管理中心，Frost＆Sullivan公司（伦敦和法兰克福）和商业周刊高级经理人课程（阿姆斯特丹和几个美国城市）。她曾在韩国首尔国立大学，本·古里安大学，圣加仑大学（瑞士）和卡利亚里大学执教EMBA课程。 1989年，当选管理学院院士，并担任其理事会和Ronin发展公司的顾问委员会成员。她的文章出现在各种杂志上，包括Strategic Management Journal, Academy of Management Review （Consulting Editor）， Academy of Management Journal, Columbia Journal of World Business, Academy of Management Executive, Journal of Business Strategy，以及 Journal of Engineering and Technology Management。
Kathryn Rudie Harrigan, Director since 1994. Member of the Audit and Regulatory Affairs Committees of the Board. In 1993 Dr. Harrigan became the first Henry R. Kravis Professor of Business Leadership at Columbia University Business School. Dr. Harrigan was previously Professor, Management Division of the Columbia University Business School and Academic Director of the Jerome A. Chazen Institute for International Business and Academic Director of the Strategy Research Center, all at Columbia University. Dr. Harrigan is a founding member of the Strategic Management Society. She has taught in several executive development programs for Columbia Business School, for Management Centre Europe London and Brussels, Frost & Sullivan (London and Frankfurt), and Business Week Executive Programs (Amsterdam and several U.S. cities). She has taught in the Executive MBA Programs of Seoul National University, Ben-Gurion University, St. Gallen University (Switzerland), and University of Cagliari. In 1989 Dr. Harrigan was elected a Fellow of the Academy of Management and has served on its Board of Governors as well as the Advisory Board of Ronin Development Corporation. She has written for and has served on the Board of Editors of various journals including the Strategic Management Journal, Academy of Management Review (Consulting Editor), Academy of Management Journal, Columbia Journal of World Business, Academy of Management Executive, Journal of Business Strategy, and Journal of Engineering and Technology Management. - Kathryn Rudie Harrigan自1994年起担任董事。审计和监管事务委员会成员。 1993年，成为哥伦比亚大学商学院的第一个Henry R. Kravis教授。曾任哥伦比亚大学商学院管理科教授，和Jerome A. Chazen学院的学术主任，国际商业和战略研究中心学术主任，均位于哥伦比亚大学。她是战略管理协会的创始成员之一。她曾执教哥伦比亚大学商学院的行政人员培训课程，欧洲伦敦和布鲁塞尔的管理中心，Frost＆Sullivan公司（伦敦和法兰克福）和商业周刊高级经理人课程（阿姆斯特丹和几个美国城市）。她曾在韩国首尔国立大学，本·古里安大学，圣加仑大学（瑞士）和卡利亚里大学执教EMBA课程。 1989年，当选管理学院院士，并担任其理事会和Ronin发展公司的顾问委员会成员。她的文章出现在各种杂志上，包括Strategic Management Journal, Academy of Management Review （Consulting Editor）， Academy of Management Journal, Columbia Journal of World Business, Academy of Management Executive, Journal of Business Strategy，以及 Journal of Engineering and Technology Management。
- Kathryn Rudie Harrigan, Director since 1994. Member of the Audit and Regulatory Affairs Committees of the Board. In 1993 Dr. Harrigan became the first Henry R. Kravis Professor of Business Leadership at Columbia University Business School. Dr. Harrigan was previously Professor, Management Division of the Columbia University Business School and Academic Director of the Jerome A. Chazen Institute for International Business and Academic Director of the Strategy Research Center, all at Columbia University. Dr. Harrigan is a founding member of the Strategic Management Society. She has taught in several executive development programs for Columbia Business School, for Management Centre Europe London and Brussels, Frost & Sullivan (London and Frankfurt), and Business Week Executive Programs (Amsterdam and several U.S. cities). She has taught in the Executive MBA Programs of Seoul National University, Ben-Gurion University, St. Gallen University (Switzerland), and University of Cagliari. In 1989 Dr. Harrigan was elected a Fellow of the Academy of Management and has served on its Board of Governors as well as the Advisory Board of Ronin Development Corporation. She has written for and has served on the Board of Editors of various journals including the Strategic Management Journal, Academy of Management Review (Consulting Editor), Academy of Management Journal, Columbia Journal of World Business, Academy of Management Executive, Journal of Business Strategy, and Journal of Engineering and Technology Management.
高管简历
中英对照 | 中文 | 英文- Samantha M. Hanley
Samantha M. Hanley，于2009年4月加入Cambrex，也曾担任助理总法律顾问和助理秘书（2013年1月以来），以及副总裁、总法律顾问和秘书（2015年2月以来）。她此前曾担任高级知识产权企业顾问、助理秘书。加入Cambrex公司之前，她曾任职Alpharma Pharmaceuticals，担任知识产权主管，也曾担任Lerner, David, Littenberg, Krumholtz & Mentlik, LLP（一个知识产权律师事务所）的副合伙人。
Samantha M. Hanley joined Cambrex in April 2009 and has served as Vice President, General Counsel and Corporate Secretary since February 2015. She previously served as Assistant General Counsel and Assistant Corporate Secretary, from January 2013 until February 2015. Ms. Hanley previously held the position of Senior Intellectual Property/Corporate Counsel and Assistant Secretary. Prior to joining Cambrex, Ms. Hanley worked at Alpharma Pharmaceuticals as Director of Intellectual Property and was an Associate with Lerner, David, Littenberg, Krumholtz & Mentlik, LLP, an intellectual property law firm.- Samantha M. Hanley，于2009年4月加入Cambrex，也曾担任助理总法律顾问和助理秘书（2013年1月以来），以及副总裁、总法律顾问和秘书（2015年2月以来）。她此前曾担任高级知识产权企业顾问、助理秘书。加入Cambrex公司之前，她曾任职Alpharma Pharmaceuticals，担任知识产权主管，也曾担任Lerner, David, Littenberg, Krumholtz & Mentlik, LLP（一个知识产权律师事务所）的副合伙人。
- Samantha M. Hanley joined Cambrex in April 2009 and has served as Vice President, General Counsel and Corporate Secretary since February 2015. She previously served as Assistant General Counsel and Assistant Corporate Secretary, from January 2013 until February 2015. Ms. Hanley previously held the position of Senior Intellectual Property/Corporate Counsel and Assistant Secretary. Prior to joining Cambrex, Ms. Hanley worked at Alpharma Pharmaceuticals as Director of Intellectual Property and was an Associate with Lerner, David, Littenberg, Krumholtz & Mentlik, LLP, an intellectual property law firm.
- Steven M. Klosk
Steven M. Klosk自2008年起担任董事。于1992年加入Cambrex公司，当选Cambrex公司的总裁和行政总裁，于2008年5月成为董事会的一员。在2007年，被任命为Cambrex公司的执行副总裁兼首席营运官，负责制药业务。从2005年至2007年担任制药公司和生物制药事业部的执行副总裁兼首席运营官。1992年至2005年，担任越来越多的要职，包括执行副总裁，负责管理。目前担任NPS（一家私人持有的包装公司）的董事，以及在新泽西州帕特森的圣若瑟医院基金董事会的董事。
Steven M. Klosk joined board of directors in 2014. He is a senior executive with extensive management experience in the life sciences indtry. He served as a Director at Cambrex Corporation (NYSE:CBM) from May 2008 through December 2019, until it was acquired by Permira and then as Director from December 2019 until June 2020. Cambrex is one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets, where he served as President and Chief Executive Officer from May 2008 through June 2020. In that role he was responsible for all aspects of Cambrex's global biness with manufacturing and R&D facilities in the United States, Sden, Italy, Estonia, Canada, Scotland, and Germany.From 2021 until April 2024, he served on the board of directors of Recipharm, a leading pharmaceutical contract development & manufacturing organization. Since 2021 he has served on the board of Formulated Solutions, a topicals contract development & manufacturing organization where he is the chairman of the board and BioIVT, a leading supplier of biologics specimens for biotech research. In addition, Mr. Klosk served on the board of Golden Arrow Merger Corp., which merged in Augt 2024 with Bolt Project Holdings Inc. (Nasdaq: BSLK), a pioneer in stainable biomaterials for consumer products. Mr. Klosk served both as a board member and an audit committee member of Bolt Project Holdings until February 2025. Mr. Klosk previoly served on the boards of BIOVECTRA, a leading small molecule and biologics CDMO until September 2024 and NJ Bio, a leading antibody drug conjugate contract research organization from March 2021 through December 2024.Mr. Klosk held other executive positions at Cambrex Corporation, including President, Executive Vice President & COO as ll as President, Pharma Biness Unit (2007 2008) where he had full P&L and balance sheet responsibility for f operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Biness Unit (2003 2007) where he was responsible for managing a highly profitable global biness with six operating units in North America and Europe. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School.- Steven M. Klosk自2008年起担任董事。于1992年加入Cambrex公司，当选Cambrex公司的总裁和行政总裁，于2008年5月成为董事会的一员。在2007年，被任命为Cambrex公司的执行副总裁兼首席营运官，负责制药业务。从2005年至2007年担任制药公司和生物制药事业部的执行副总裁兼首席运营官。1992年至2005年，担任越来越多的要职，包括执行副总裁，负责管理。目前担任NPS（一家私人持有的包装公司）的董事，以及在新泽西州帕特森的圣若瑟医院基金董事会的董事。
- Steven M. Klosk joined board of directors in 2014. He is a senior executive with extensive management experience in the life sciences indtry. He served as a Director at Cambrex Corporation (NYSE:CBM) from May 2008 through December 2019, until it was acquired by Permira and then as Director from December 2019 until June 2020. Cambrex is one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets, where he served as President and Chief Executive Officer from May 2008 through June 2020. In that role he was responsible for all aspects of Cambrex's global biness with manufacturing and R&D facilities in the United States, Sden, Italy, Estonia, Canada, Scotland, and Germany.From 2021 until April 2024, he served on the board of directors of Recipharm, a leading pharmaceutical contract development & manufacturing organization. Since 2021 he has served on the board of Formulated Solutions, a topicals contract development & manufacturing organization where he is the chairman of the board and BioIVT, a leading supplier of biologics specimens for biotech research. In addition, Mr. Klosk served on the board of Golden Arrow Merger Corp., which merged in Augt 2024 with Bolt Project Holdings Inc. (Nasdaq: BSLK), a pioneer in stainable biomaterials for consumer products. Mr. Klosk served both as a board member and an audit committee member of Bolt Project Holdings until February 2025. Mr. Klosk previoly served on the boards of BIOVECTRA, a leading small molecule and biologics CDMO until September 2024 and NJ Bio, a leading antibody drug conjugate contract research organization from March 2021 through December 2024.Mr. Klosk held other executive positions at Cambrex Corporation, including President, Executive Vice President & COO as ll as President, Pharma Biness Unit (2007 2008) where he had full P&L and balance sheet responsibility for f operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Biness Unit (2003 2007) where he was responsible for managing a highly profitable global biness with six operating units in North America and Europe. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School.
- Gregory P. Sargen
Gregory P. Sargen于2003年2月加入Cambrex公司。2007年2月，担任副总裁兼财务总监。自2011年1月起担任执行副总裁兼首席财务官。曾担任财务副总裁。此前，从1999年到2002年曾在Exp@nets公司工作，担任各种角色包括执行副总裁，金融/财务总监，副总裁/财务总监。从1996年到1998年，担任飞世尔科技国际化工制造部的财务副总裁和总监。还曾在Merck & Company, Inc., Heat and Control, Inc.，和 Deloitte & Touche。担任财务、会计和审计等职位。
Gregory P. Sargen,was appointed to the Board of Directors in November 2017. Mr. Sargen most recently served as Chief Financial Officer and Executive Vice President, Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) ("Cambrex"), a global manufacturer and provider of services to life sciences companies, from 2007 until early 2020, when Cambrex was acquired by a private equity company. Mr. Sargen previously served as Executive Vice President, Corporate Development and Strategy, Chief Financial Officer, and Vice President, Finance of Cambrex. Prior to Cambrex, Mr. Sargen served as Executive Vice President, Chief Financial Officer of Expanets, Inc., Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen also serves on the board of Protara Therapeutics (NASDAQ:TARA), a drug development company, Kindeva Drug Delivery LLC, a privately held company focused on complex drug delivery solutions, Veranova, a privately held contract development and manufacturer of small molecule active pharmaceutical ingredients, and Umoja Biopharma, a privately held biotechnology company. Mr. Sargen serves as chairman of the Audit Committee for each of the foregoing companies. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.- Gregory P. Sargen于2003年2月加入Cambrex公司。2007年2月，担任副总裁兼财务总监。自2011年1月起担任执行副总裁兼首席财务官。曾担任财务副总裁。此前，从1999年到2002年曾在Exp@nets公司工作，担任各种角色包括执行副总裁，金融/财务总监，副总裁/财务总监。从1996年到1998年，担任飞世尔科技国际化工制造部的财务副总裁和总监。还曾在Merck & Company, Inc., Heat and Control, Inc.，和 Deloitte & Touche。担任财务、会计和审计等职位。
- Gregory P. Sargen,was appointed to the Board of Directors in November 2017. Mr. Sargen most recently served as Chief Financial Officer and Executive Vice President, Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) ("Cambrex"), a global manufacturer and provider of services to life sciences companies, from 2007 until early 2020, when Cambrex was acquired by a private equity company. Mr. Sargen previously served as Executive Vice President, Corporate Development and Strategy, Chief Financial Officer, and Vice President, Finance of Cambrex. Prior to Cambrex, Mr. Sargen served as Executive Vice President, Chief Financial Officer of Expanets, Inc., Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen also serves on the board of Protara Therapeutics (NASDAQ:TARA), a drug development company, Kindeva Drug Delivery LLC, a privately held company focused on complex drug delivery solutions, Veranova, a privately held contract development and manufacturer of small molecule active pharmaceutical ingredients, and Umoja Biopharma, a privately held biotechnology company. Mr. Sargen serves as chairman of the Audit Committee for each of the foregoing companies. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.
- Shawn P. Cavanagh
Shawn P. Cavanagh于2011年1月加入Cambrex公司。目前担任执行副总裁兼首席运营官。从2007年到2009年受雇于Lonza，该公司收购了Cambrex Bioproducts，最后担任Lonza生物科学总裁。从1999年至2007年任职于Cambrex Bioproducts。在Cambrex Bioproducts担任多个要职，包括Cambrex Bioproducts的总裁。在加入Cambrex Bioproducts之前，在FMC公司担任各种管理和工程职位。
Shawn P. Cavanagh joined Cambrex in January 2011 and has served as Executive Vice President and Chief Operating Officer since he joined Cambrex. From 2007 to 2009 Mr. Cavanagh was employed with Lonza, which purchased Cambrex Bioproducts, most recently as President of Lonza Bioscience. From 1999 to 2007 Mr. Cavanagh worked for Cambrex Bioproducts. While at Cambrex Bioproducts, Mr. Cavanaugh held several positions of increasing responsibility including President of Cambrex Bioproducts. Prior to joining Cambrex Bioproducts, Mr. Cavanagh held various management and engineering positions with FMC Corporation.- Shawn P. Cavanagh于2011年1月加入Cambrex公司。目前担任执行副总裁兼首席运营官。从2007年到2009年受雇于Lonza，该公司收购了Cambrex Bioproducts，最后担任Lonza生物科学总裁。从1999年至2007年任职于Cambrex Bioproducts。在Cambrex Bioproducts担任多个要职，包括Cambrex Bioproducts的总裁。在加入Cambrex Bioproducts之前，在FMC公司担任各种管理和工程职位。
- Shawn P. Cavanagh joined Cambrex in January 2011 and has served as Executive Vice President and Chief Operating Officer since he joined Cambrex. From 2007 to 2009 Mr. Cavanagh was employed with Lonza, which purchased Cambrex Bioproducts, most recently as President of Lonza Bioscience. From 1999 to 2007 Mr. Cavanagh worked for Cambrex Bioproducts. While at Cambrex Bioproducts, Mr. Cavanaugh held several positions of increasing responsibility including President of Cambrex Bioproducts. Prior to joining Cambrex Bioproducts, Mr. Cavanagh held various management and engineering positions with FMC Corporation.
- James G. Farrell
James G. Farrell于2005年9月加盟Cambrex公司，担任公司财务总监。 2007年7月起担任副总裁兼财务总监，2008中他受聘于PDI公司担任副总裁兼财务总监/临时财务总监。从1994年直到2005年，在英格索兰公司工作，最后担任主任，负责会计政策、程序和外部报告。1988年至1994年在安永会计师事务所工作，最后担任审计经理。
James G. Farrell joined Cambrex in September 2005 as Corporate Controller. He has served as Vice President and Corporate Controller since July 2007 except for a portion of 2008 when Mr. Farrell was employed by PDI, Inc. as Vice President and Corporate Controller/Interim Chief Financial Officer. From 1994 until 2005 he was with Ingersoll-Rand Company, most recently as Director, Accounting Policy, Procedures and External Reporting. Mr. Farrell was with Ernst & Young from 1988 to 1994 most recently as Audit Manager.- James G. Farrell于2005年9月加盟Cambrex公司，担任公司财务总监。 2007年7月起担任副总裁兼财务总监，2008中他受聘于PDI公司担任副总裁兼财务总监/临时财务总监。从1994年直到2005年，在英格索兰公司工作，最后担任主任，负责会计政策、程序和外部报告。1988年至1994年在安永会计师事务所工作，最后担任审计经理。
- James G. Farrell joined Cambrex in September 2005 as Corporate Controller. He has served as Vice President and Corporate Controller since July 2007 except for a portion of 2008 when Mr. Farrell was employed by PDI, Inc. as Vice President and Corporate Controller/Interim Chief Financial Officer. From 1994 until 2005 he was with Ingersoll-Rand Company, most recently as Director, Accounting Policy, Procedures and External Reporting. Mr. Farrell was with Ernst & Young from 1988 to 1994 most recently as Audit Manager.